Increased expression of cardiac phosphatases in patients with end-stage heart failure.
Type 1 phosphatase activity was increased in membrane vesicles from failing human ventricles compared with non-failing controls. Likewise, expression of the mRNA encoding for type 1 phosphatase was enhanced by 37%. The present study provides evidence that alterations of phosphatase activity coincide with end-stage heart failure. Thus, enhanced activity of phosphatases may be causally related to heart failure and/or may aggravate the well known decreased cardiac responsiveness to positive inotropic agents in end-stage heart failure.
Neumann
J
J
Institut für Pharmakologie und Toxikologie der Westfälischen Wilhelms-Universität, Münster, FRG.
Eschenhagen
T
T
Jones
L R
LR
Linck
B
B
Schmitz
W
W
Scholz
H
H
Zimmermann
N
N
D000262:Adenylyl Cyclases / Q000378:metabolism; D000328:Adult; D000818:Animals; D015152:Blotting, Northern; D002311:Cardiomyopathy, Dilated / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology*; D006352:Heart Ventricles / Q000378:metabolism*; D006801:Humans; D008297:Male; D008566:Membranes / Q000378:metabolism; D008875:Middle Aged; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics*; D051381:Rats
D010744:Phosphoric Monoester Hydrolases; D000262:Adenylyl Cyclases